Featured Research

from universities, journals, and other organizations

Antibody-coated stents: Indication of disadvantages

Date:
November 14, 2012
Source:
Institute for Quality and Efficiency in Health Care
Summary:
If coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. If this stent is coated with antibodies instead of drugs, the risk of subsequent myocardial infarction or re-operation increases in certain patients, according to a new report.

If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary. This is the conclusion reached in the rapid report of the German Institute for Quality and Efficiency in Health Care (IQWiG), as published on 12 October 2012.

Related Articles


Focus on patients with a high risk of restenosis

The Federal Joint Committee (G-BA) had commissioned IQWiG to investigate the advantages and disadvantages of antibody-coated stents in comparison to alternative measures, focussing on patients with coronary heart disease (CHD) at high risk of restenosis. This depends on factors including the duration and degree of the narrowing as well as its precise localization. The curvature of the affected vessels can also play a role.

Even stented vessels may become blocked again

Narrowed coronary vessels are generally expanded by surgery and stabilized with stents (tubes of wire mesh). But even vessels supported by stents can become blocked again, if there is excessive tissue growth. Re-operation is then necessary (revascularization). Moreover, stents are foreign bodies. If they are not fully covered with a smooth cell layer (epithelium), platelets are more likely to stick to them and blood clots (thromboses) are more likely to form on them. It is attempted to counteract these two main risks (thrombosis formation and tissue proliferation) by specifically coating the stent and by treating the patient with anticoagulants.

Risk of thrombosis increases

The first generation of stents consisted of pure metal (bare-metal stents, BMS) and are now rarely used for patients at high risk of restenosis. The second generation of stents were coated and released small quantities of drugs (drug-eluting stents, DES). These drugs are meant to inhibit cell growth and thus avoid restenosis and the need for revascularization.

On the other hand, this coating delays incorporation of the stent, thus increasing the risk of thrombosis. Therefore patients with a DES must generally take antithrombotic drugs for at least 12 months after the operation. The active substances acetylsalicylic acid (ASS) and clopidogrel -- so called platelet inhibitors -- are most frequently used.

Antibody-stents are intended to reduce the use of anticoagulants

The third generation of stents act by using specific antibodies to stimulate cells growing into the vascular wall to form epithelium. This is supposed to accelerate the incorporation of the wire network and reduce the risk of thrombosis. The manufacturer claims that this greatly shortens the period for which antithrombotic drugs must be taken, thus helping to avoid the side effect of an increased tendency to bleed and also helping to reduce costs.

Two of three studies susceptible to bias

Three randomized controlled trials (RCTs) were available to IQWiG. Two studies compared antibody-stents with DES; one study compared antibody-stents with BMS. One DES study and one BMS study had only a few participants and were prematurely discontinued. These discontinuations were not planned, i.e. the criteria for stopping the studies had not been specified before the start of the studies. Moreover, it was unclear in one of the studies whether the randomized allocation to the two treatment groups was adequately concealed. These studies were thus highly susceptible to bias and the results can only be used to a limited extent.

In accordance with the mechanism of action of antibody-stents, the patients in all three studies were only given clopidogrel for one month. In contrast, the patients in the control groups were given clopidogrel for either 3 months (DES) or for six months (BMS).

The comparison with DES is mainly based on a single study

The comparative benefit assessment of DES- and antibody-stents is mainly based on a single study (TRIAS-HR). This was comparatively large -- with 600 patients -- and the risk of bias was low. Of the 304 patients who had been given an antibody-stent, 13 (4.3%) suffered a myocardial infarction, in comparison with 5 of 318 patients (1.6%) in the control group with DES.

The results for antibody-stents were also less favourable with respect to revascularization: re-operation was necessary for 71 of 297 (23.9%) patients in the antibody-stent group, in comparison with 51 of 315 patients (16.2%) in the DES group. As this conclusion was only based on a single study, IQWiG considers that there is no proof, but only an indication, of lesser benefit. This applies both to the outcome of myocardial infarction and to the outcome of revascularization.

An additional outcome criterion was a composite outcome including myocardial infarction and deaths due to other types of heart failure (cardiac mortality). Here too the results suggest that the antibody-stents are at a disadvantage. However, this is not an indication, but only a hint.

Mechanism of action of antibody-stents is questionable

The manufacturer of the antibody-stent claims that clopidogrel can be administered for a shorter period with their product. This may be of particular importance for patients undergoing surgery, as platelet inhibitors increase the risk of bleeding. Moreover, antibody-stents are supposed to be particularly effective in preventing restenoses in the vessels that are primarily affected.

Jόrgen Windeler, the IQWiG Director, commented that, if this was the case, the rate of revascularization in these vessels would be lower. However, the TRIAS-HR study suggested that the opposite was the case. This called the mechanism of action of antibody-stents into doubt. It could also not be excluded that the disadvantage of antibody-stents found in the studies was due to the early discontinuation of clopidogrel. He added that antibody-stents were just another example of how not only the medical device, but also its manner of application, were decisive, and that if we wanted reliable information on benefit, we had to consider both the product and its application.

Benefit studies on medical devices are both feasible and necessary

Contrary to what the manufacturers of medical devices often assert, these benefit studies are feasible. According to Jόrgen Windeler: "If you take the patient's safety seriously, you have to insist on these studies. Antibody-stents have been used for many years, but we don't know how many patients have received this intervention. It is only now that we learn that its harm outweighs its benefit."

Procedure of report production

The G-BA commissioned IQWiG to prepare the report in an accelerated process, known as a "rapid report." Unlike the normal procedure, no preliminary reports are published in this case. Although a draft version of the report is reviewed by external experts, no hearing at which all interested parties can comment takes place.

The first report (Version 1.0) was prepared in the middle of August 2012 and sent to the G-BA. Shortly afterwards, the Institute was sent additional and previously unpublished data on the decisive study TRIAS-HR, which had been requested by the Institute from the responsible research group in Amsterdam (data on the overall rate of myocardial infarctions and revascularization). The report was then revised and Version 1.1 sent to the G-BA at the start of September 2012.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Antibody-coated stents: Indication of disadvantages." ScienceDaily. ScienceDaily, 14 November 2012. <www.sciencedaily.com/releases/2012/11/121114113454.htm>.
Institute for Quality and Efficiency in Health Care. (2012, November 14). Antibody-coated stents: Indication of disadvantages. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2012/11/121114113454.htm
Institute for Quality and Efficiency in Health Care. "Antibody-coated stents: Indication of disadvantages." ScienceDaily. www.sciencedaily.com/releases/2012/11/121114113454.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins